The U.K.’s Medicines and Healthcare products Regulatory Agency, MHRA, has approved GSK‘s (GSK) gepotidacin, also known as Blujepa, a new kind of oral antibiotic pill to treat uncomplicated urinary tract infections in females aged 12 years and older, weighing at least 40kg. The new marketing authorisation was granted on 27 August 2025 to GSK plc. The approval of gepotidacin is based on two multicentre, randomised, active-controlled Phase 3 trials – large international studies where participants with uncomplicated UTIs were randomly assigned to receive either gepotidacin or the standard treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s Promising Phase 3 Study on Multiple Myeloma Treatment: A Market Game Changer?
- GSK’s Promising Phase 3 Study on Relapsed SCLC: A Potential Game Changer
- Veeva highlights GSK Vault CRM go-live across Europe
- GSK Vault CRM rollout a ‘key milestone’ for Veeva, says Raymond James
- Trump Weekly: Trump weighs stake in Intel, candidates for Fed Chair